Literature DB >> 31125406

TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing.

Lan Xiao1,2, Fang Wei1,2, Fang Liang2,3, Qiao Li2, Hao Deng3, Shiming Tan3, Shuai Chen4, Fang Xiong1,2, Can Guo2, Qianjin Liao4, Xiayu Li3, Wenling Zhang2, Minghua Wu2, Yanhong Zhou2, Bo Xiang2, Ming Zhou2, Xiaoling Li2, Wei Xiong2, Zhaoyang Zeng1,2,3, Guiyuan Li1,2,3.   

Abstract

Cancer is a complex disease, which may involve multiple tumor susceptibility genes that mediate the occurrence and development of tumor molecular events. This study aimed to identify new genetic loci using genome-wide linkage analysis and whole-exome sequencing in a rare, large multi-cancer pedigree recently found in China. We performed high-throughput single-nucleotide polymorphism (SNP) array and linkage analyses of 24 core members of this pedigree and found that the disease susceptibility locus in the multi-cancer pedigree was mapped to chromosome 3q24-26. We also used microsatellites to further validate the results of the SNP locus linkage analysis. Furthermore, we sequenced the whole exome of three members in this pedigree and identified a novel mutant of transforming growth factor β stimulated clone 22 domain family, member 2 (TSC22D2, c.-91T-C) cosegregated with the cancer phenotype. This change was at a highly conserved position, and the exome results were validated using linkage analysis. Moreover, we found the histone H4 transcription factor (HINFP) binds to the promoter region of TSC22D2 and may regulate its transcription. In conclusion, our findings are of great significance to the early pathogenesis of tumors and contribute to the search for molecular targets for the early prevention and treatment of tumors.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2019        PMID: 31125406     DOI: 10.1093/carcin/bgz095

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

Review 1.  Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.

Authors:  Daixi Ren; Yuze Hua; Boyao Yu; Xin Ye; Ziheng He; Chunwei Li; Jie Wang; Yongzhen Mo; Xiaoxu Wei; Yunhua Chen; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2020-01-30       Impact factor: 27.401

Review 2.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

3.  circSETD3 regulates MAPRE1 through miR-615-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma.

Authors:  Le Tang; Wei Xiong; Lishen Zhang; Dan Wang; Yian Wang; Yingfen Wu; Fang Wei; Yongzhen Mo; Xiangchan Hou; Lei Shi; Fang Xiong; Shanshan Zhang; Zhaojian Gong; Qianjin Liao; Bo Xiang; Wenling Zhang; Ming Zhou; Xiaoling Li; Guiyuan Li; Can Guo; Zhaoyang Zeng
Journal:  Oncogene       Date:  2020-10-29       Impact factor: 9.867

4.  LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma.

Authors:  Ting Tang; Liting Yang; Yujian Cao; Maonan Wang; Shanshan Zhang; Zhaojian Gong; Fang Xiong; Yi He; Yujuan Zhou; Qianjin Liao; Bo Xiang; Ming Zhou; Can Guo; Xiaoling Li; Yong Li; Wei Xiong; Guiyuan Li; Zhaoyang Zeng
Journal:  Mol Oncol       Date:  2020-06-13       Impact factor: 6.603

5.  GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma.

Authors:  Chunmei Fan; Chaofeng Tu; Peng Qi; Can Guo; Bo Xiang; Ming Zhou; Xiayu Li; Xu Wu; Xiaoling Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  J Cancer       Date:  2019-06-24       Impact factor: 4.207

Review 6.  Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis.

Authors:  Ke Jin; Shufei Wang; Yazhuo Zhang; Mengfang Xia; Yongzhen Mo; Xiaoling Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong; Yi He
Journal:  Cell Mol Life Sci       Date:  2019-07-15       Impact factor: 9.261

Review 7.  N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies.

Authors:  Fenghua Tan; Mengyao Zhao; Fang Xiong; Yumin Wang; Shanshan Zhang; Zhaojian Gong; Xiayu Li; Yi He; Lei Shi; Fuyan Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Yong Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong; Can Guo
Journal:  J Exp Clin Cancer Res       Date:  2021-04-29

Review 8.  Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA.

Authors:  Pan Wu; Yongzhen Mo; Miao Peng; Ting Tang; Yu Zhong; Xiangying Deng; Fang Xiong; Can Guo; Xu Wu; Yong Li; Xiaoling Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2020-02-04       Impact factor: 27.401

9.  The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer.

Authors:  Junshang Ge; Jie Wang; Hui Wang; Xianjie Jiang; Qianjin Liao; Qian Gong; Yongzhen Mo; Xiaoling Li; Guiyuan Li; Wei Xiong; Jin Zhao; Zhaoyang Zeng
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

10.  Upregulation of long non-coding RNA LOC284454 may serve as a new serum diagnostic biomarker for head and neck cancers.

Authors:  Chunmei Fan; Jinpeng Wang; Yanyan Tang; Shanshan Zhang; Fang Xiong; Can Guo; Yanhong Zhou; Zheng Li; Xiaoling Li; Yong Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  BMC Cancer       Date:  2020-09-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.